Loading...
MTBL.Y logo

Moatable, Inc.OTCPK:MTBL.Y Stock Report

Market Cap US$4.6m
Share Price
US$0.30
My Fair Value
n/a
1Y-74.5%
7D0%
1D
Portfolio Value
​
View

Moatable, Inc.

OTCPK:MTBL.Y Stock Report

Market Cap: US$4.6m

Moatable (MTBL.Y) Stock Overview

Engages in the software as a service business in the United States and internationally. More details

MTBL.Y fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings have grown 36.2% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap ($5M)

Shares are highly illiquid


MTBL.Y Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Moatable, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Moatable
Historical stock prices
Current Share PriceUS$0.28
52 Week HighUS$3.33
52 Week LowUS$0.0003
Beta10.63
1 Month Change-22.22%
3 Month Change-91.25%
1 Year Change-74.55%
3 Year Change-75.22%
5 Year Change-97.66%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Analysis Article • Sep 14

We're Keeping An Eye On Moatable's (NYSE:MTBL) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 02

Here's Why We're Not Too Worried About Renren's (NYSE:RENN) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Dec 19

Best Idea: Renren And Beyond

Summary Three things I look for when looking at companies. 2022: It was all about Renren. 2023: What ideas are out there? YCharts Best Ideas Each year, I highlight one top position as a best idea for the subsequent year. This year, the idea has been Renren (RENN), one of my top three holdings. How do I pick? I look for three things: Something safe, lucrative, and uncorrelated with the overall markets. Bottoms up! I look for ways to make money in any market – up, down or sideways. Macro prognosticators are far greater in quantity than quality. What I don’t do: Macro I stay out of the whole discussion of which way the stock market will go. I have no idea. I doubt many of the people who make bold macro calls get it right a statistically significant percentage of the time. What I do: Events Instead I focus on discreet corporate events that unlock shareholder value and do detailed firm-level analysis to find and exploit them to make money in any market. What kind of events? Mostly litigation, M&A, and in particular merger securities (which overlaps quite a bit with litigation). What are we really doing here? Counterparty selection. Avoiding being the patsy. Narrowing down who you’re competing against due to narrow mandates and complexity. Renren My best idea for 2022 was Renren. The year is not yet out but with the S&P 500 down 18%, RENN is up over 120% year to date. It started the year under $15. It will end the year with a $31.62 cash distribution. This was the result of a complex litigation that I was intimately involved with for a long time. It was safe, lucrative, and had absolutely nothing whatsoever to do with what the overall stock market did - it just happened to be publicly traded. When first presented, I estimated the probability of its upside scenario at 90%, now that's 100%. Excluding the cash distribution, I estimated that equity stub would be worth at least $1 and maybe as much as $4. Today, it costs under $1. It's exactly what I look for when sizing a top position and picking an annual idea. Spectrum As I approach the decision on what to name my best idea for 2023, I’m looking for another case that will be safe, lucrative, and uncorrelated with the stock market. One candidate is Spectrum Brands (SPB). It finished this past quarter under $40 per share, has recovered a bit but still trades for under $60 and is worth over $80. The kicker, as with Renren, is litigation. The US Department of Justice sued to block a transformative asset sale that would pay SPB in cash more than their entire market cap. It's a great deal but the current administration is quite wary of deals and claims this would be monopolistic. My view is that the case is weak, especially after the companies named a strong buyer for the entire overlapping product lines. The deal will probably get done by the middle of next year, which could catapult SPB shares regardless of what the rest of the market is doing. Antitrust I blurted out two edgy, actionable ideas – a favorite recent one and upcoming one. But now let me back up to discuss M&A heading into 2023 more generally. This category is a great solution for capital if you don’t know what the market is going to do next. But the solution has a few problems worth highlighting. First the aforementioned antitrust agencies: They're particularly hostile at the moment and will bring a lot of suits to block deals, especially customer-facing deals in tech or healthcare. I like cases such as SPB that are already in front of a judge. The FTC and DoJ can bring cases, but they have to make their case. I prefer to avoid getting hit with the stock price reaction to such suits and then load up when the government brings dumb ones likely to lose. Financing A second problem: The credit market for deal financing is quite weak. If buyers need to raise a lot of debt from banks for their deals, those deals are not likely to get done. While antitrust has been making life hard for strategic deals, the credit market has been making life particularly hard for private equity’s leveraged buyouts. In fact one of the best places in the market for short ideas in 2022 has been in speculated takeover candidates. Many of these made it into the press without making it to definitive merger agreements. So I like M&A but I'm wary of both antitrust risk and financing risk – what kind of deal does that leave me? Looking back at 2022, that left me Twitter, my biggest and best risk arbitrage position ever. Activision Looking forward, here are some of the opportunities. Microsoft (MSFT) is buying Activision (ATVI) in a deal that the FTC is trying to block on dubious antitrust grounds. They can delay it and even interfere enough to stop it, especially if they get an assist from foreign regulators such as the UK’s CMA. But the deal price is $95, as of this writing the shares cost about $77 and they aren’t worth all that much less than they cost even without the deal. So this was not worth it before the antitrust problems were fully priced in but is increasingly interesting since then. This may be one of the best definitive merger arbs at the moment, so is another I have my eye on. Amplify In terms of deal financing, eventually the credit market will stabilize. It doesn’t even need to strengthen as much as just settle down so participants know where to price debt. That’s why I’m focusing on situations for 2023 that need a few more months anyways. One in particular is Amplify Energy (AMPY). It costs about $7 per share and is worth at least twice that. The value is likely to be unlocked well before the end of next year. First, they have a damaged pipeline that needs fixing. Then, they have commodity hedges that can be rolled off. They will be able to use the repaired pipe for the cash flow necessary to completely deleverage their balance sheet. At which point, this wildly undervalued and undersized oil and gas company will be a layup of a sale candidate to a larger strategic buyer. This is safe, lucrative, uncorrelated, and likely to be a one-decision investment from here. If you can buy any under $10 per share, you will probably get a significant premium to that price in a sale. Ideally, the timing could work out so that it closes late enough in 2023 to get long-term tax treatment on what could be a monster gain. This is my biggest and favorite position at the moment (a best idea candidate, but it's volatile, so no decision until closer to Year End so I can see the starting price). Abiomed This one will actually be over (in terms of the window for taking advantage of it) by month end. It's a merger security that avoids any antitrust or financing risk. You could lose a little over a dollar (depending on the specific price you get) or make over $33. Johnson & Johnson (JNJ) is buying Abiomed (ABMD). It has already secured all regulatory approvals including the US, Germany, Austria, and Japan. Then by the end of this week they will tender for shares and send you $380 in cash per share, returning approximately your entire cost basis. That leaves you with, at worst, a tie. Then what? Then you get a non-tradable contingent value right worth up to $35. Sometimes these pay out, sometimes they don’t, and often they settle years later when holders sue the issuers over their treatment. You’re paying just over a dollar (I paid less than nothing) for a ticket that could settle or payout many times that. Details from the offer:
Seeking Alpha • Nov 10

Renren Non-GAAP EPS of $2.77, revenue of $21.3M

Renren press release (NYSE:RENN): 1H Non-GAAP EPS of $2.77. Revenue of $21.3M (+42.0% Y/Y).
Seeking Alpha • Apr 28

Renren: Our Best Long For 2022

How has RENN done so far? What is it worth? What happens next?
Seeking Alpha • Jan 19

Renren: An Update On Our Best Idea For 2022

Sifting the World presented our best idea to members last month. A lot has happened since then in the market and this stock. Here is why it is a huge opportunity today at under $25.
Seeking Alpha • Jan 10

Renren Is So Bad It's Good

StW’s best idea for 2022. A disastrous – but appealable – decision. An uncorrelated opportunity for the New Year.
Seeking Alpha • Oct 18

Renren In Search Of Identity As Its Stock Surges On Lawsuit Settlement

A 45% surge in shares of Renren, once pegged as the ‘Facebook of China,’ earlier this month was fueled by settlement of a shareholder lawsuit. Despite a $600 million market value after the jump, company is still in search of a long-term business model. In trying to stay alive and thrive during the years when its networking platform was in decline, Chairman Chen Yizhou steered Renren in a new direction by buying stakes in startups that had little to do with the social media.
Analysis Article • Feb 15

What Type Of Shareholders Make Up Renren Inc.'s (NYSE:RENN) Share Registry?

If you want to know who really controls Renren Inc. ( NYSE:RENN ), then you'll have to look at the makeup of its share...

Shareholder Returns

MTBL.YUS SoftwareUS Market
7D0%8.6%1.6%
1Y-74.5%-1.1%28.2%

Return vs Industry: MTBL.Y underperformed the US Software industry which returned -1.1% over the past year.

Return vs Market: MTBL.Y underperformed the US Market which returned 28.2% over the past year.

Price Volatility

Is MTBL.Y's price volatile compared to industry and market?
MTBL.Y volatility
MTBL.Y Average Weekly Movementn/a
Software Industry Average Movement9.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: MTBL.Y's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine MTBL.Y's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002400Joe Chenwww.moatable.com

Moatable, Inc. engages in the software as a service business in the United States and internationally. The company develops Chime, an all-in-one real estate sales acceleration and client lifecycle management platform that allows real estate professionals to obtain and nurture leads, close transactions, and retain their clients; and Trucker Path, a driver-centric online transportation management platform to make freight transportation fast, reliable, and efficient. It also provides online and mobile services for the trucking industry in North America.

Moatable, Inc. Fundamentals Summary

How do Moatable's earnings and revenue compare to its market cap?
MTBL.Y fundamental statistics
Market capUS$4.60m
Earnings (TTM)-US$1.33m
Revenue (TTM)US$75.16m
0.1x
P/S Ratio
-3.5x
P/E Ratio

Is MTBL.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MTBL.Y income statement (TTM)
RevenueUS$75.16m
Cost of RevenueUS$19.13m
Gross ProfitUS$56.03m
Other ExpensesUS$57.36m
Earnings-US$1.33m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.081
Gross Margin74.55%
Net Profit Margin-1.77%
Debt/Equity Ratio30.2%

How did MTBL.Y perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/01 17:36
End of Day Share Price 2026/05/29 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moatable, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alicia YapBarclays
Eddie LeungBofA Global Research
Muzhi LiCitigroup Inc